Open AccessAn International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis
Author(s) -
Mark Lebwohl,
Enno Christophers,
Richard Langley,
Jean Paul Ortonne,
Janet L. Roberts,
C.E.M. Griffiths
Publication year - 2003
Publication title -
archives of dermatology
Language(s) - English
Resource type - Journals
eISSN - 1538-3652
pISSN - 0003-987X
DOI - 10.1001/archderm.139.6.719
Subject(s) - medicine , psoriasis area and severity index , tolerability , psoriasis , placebo , plaque psoriasis , intramuscular injection , dosing , randomized controlled trial , clinical trial , gastroenterology , dermatology , adverse effect , pathology , alternative medicine
Alefacept, human lymphocyte function-associated antigen 3/immunoglobulin 1 fusion protein, binds to CD2 molecules on the surface of activated T cells, selectively targeting memory-effector (CD45RO+) T cells, which comprise more than 75% of T cells in psoriatic plaques.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom